By Paul Goldberg. Top pay may not be that of listed top person.

(2020). From 1993 until he joined the University of Pennsylvania, he was affiliated with the University of Chicago, where he was professor of medicine, a Howard Hughes investigator, and director of the Gwen Knapp Center for Lupus and Immunology Research.

He was paid $70,000 in cash by Charles River in 2017, plus $215,050 in stock. Laboratory Member. Education and career. More About The Craig Thompson Lab. Vardhana, S. A., Hwee, M. A., Berisa, M., Wells, D. K., Yost, K. E., King, B., Smith, M., Herrera, P. S., Chang, H. Y., Satpathy, A. T., van den Brink, M., Cross, J. R., & Thompson, C. B. The compensation for the two corporate boards is in addition to what he is paid as chief executive at Memorial Sloan Kettering, the nonprofit institution that is one of the nation's leading cancer centers. A task force that was created in the wake of the crisis over conflicts of interest is considering a policy that would prohibit executives from holding such roles, hospital leaders have said. Li, A. M., Ducker, G. S., Li, Y., Seoane, J.

Nature immunology, 21(9), 1022–1033. King, B., Araki, J., Palm, W., & Thompson, C. B.

(2019). In an interview Tuesday, Dr. Nadeem R. Abu-Rustum, the president of the medical staff, said a small number of doctors had wanted a no-confidence vote in the hospital’s leadership, but were now satisfied by Dr. Thompson’s decision. [16][17][18][19], Thompson holds more than 30 patents related to immunotherapy and apoptosis, and is a founder of three biotechnology companies.

Craig B. Thompson, MD President and CEO, Memorial Sloan Kettering Cancer Center The Thompson laboratory has proposed that the basis of metazoan cell survival is determined by the inability of cells to take up nutrients in a cell-autonomous fashion.

Thompson has studied how genes regulate apoptosis and metabolism, and investigated their application in treating cancer.

At one meeting with hospital staff, Dr. Thompson apologized for his handling of staff reaction to the issues outlined in the articles, and acknowledged that he had not adequately reined in the industry relationships of the hospital’s former chief medical officer, Dr. José Baselga, who has since resigned.

Postdoctoral fellow.

Print. Xin Cai. The company was founded by Memorial Sloan Kettering insiders, including a member of the executive board, the chair of the pathology department and the head of a research lab. Agata (Aggie) Bielska. After members of the pathology lab objected to the deal, the head of the department announced he would divest his stake. Dr. Craig B. Thompson, the chief executive of Memorial Sloan Kettering Cancer Center, said Tuesday that he would resign his seats on the boards of drug maker Merck and another public company, the latest fallout from a widening institutional reckoning over relationships between cancer center leaders and for-profit health care companies.

A., Xiao, Y., Melemenidis, S., Zhou, Y., Liu, L., Vanharanta, S., Graves, E. E., Rankin, E. B., Curtis, C., Massagué, J., Rabinowitz, J. D., Thompson, C. B., & Ye, J. His discoveries in growth factor regulation of nutrient uptake and metabolism have provided direct mechanistic links between cellular metabolism and cell growth and survival.

At another meeting, reserved for medical staff members, some doctors said they were interested in calling a no-confidence vote in the hospital’s top leaders, and asked what steps they needed to take to do that, according to several participants in the meeting. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.

His group discovered the first Bcl-2 homolog to be identified, Bcl-Xl, and described the first BH3-only containing regulatory family member, Bcl-xS. Center for Molecular Imaging & Nanotechnology, Gerstner Sloan Kettering Graduate School of Biomedical Sciences, Major Trends in Modern Cancer Research 2013: Introduction with Memorial Sloan Kettering’s President and CEO, Major Trends in Modern Cancer Research 2011: Opening Remarks, Major Trends in Modern Cancer Research 2012: Discussion with Memorial Sloan Kettering’s President, Programs for College & High School Students. This data is updated annually.

[1], Thompson’s laboratory undertakes basic research in the fields of cancer biology and immunology. Proline biosynthesis is a vent for TGFβ-induced mitochondrial redox stress.

Yap/Taz promote the scavenging of extracellular nutrients through macropinocytosis. [23], In December 2011, The University and its Abramson Family Cancer Research Institute sued Thompson after his move to Memorial Sloan Kettering, charging that he had made use of research conducted at the University of Pennsylvania to start a biotechnology company, Agios Pharmaceuticals that Thompson had co-founded in 2007 while still at the University.

Print. Transsulfuration Activity Can Support Cell Growth upon Extracellular Cysteine Limitation. A., Xiao, Y., Melemenidis, S., Zhou, Y., Liu, L., Vanharanta, S., Graves, E. E., Rankin, E. B., Curtis, C., Massagué, J., Rabinowitz, J. D., Thompson, C. B., & Ye, J. A spokesman for the hospital said the compensation Dr. Thompson received from both companies this year would be deferred until he is 72. Santosha Vardhana. This data reflects interests that may or may not still exist. Thompson identified the evolutionary duplication of CD28 into CD28 and CTLA-4 and demonstrated that CTLA4 had an inhibitory effect on immune activation. Dr. Thompson, 65, received $300,000 in compensation from Merck in 2017, according to company financial filings.

Senior Research Technician .

Schwörer, S., Berisa, M., Violante, S., Qin, W., Zhu, J., Hendrickson, R. C., Cross, J. R., & Thompson, C. B. Impaired mitochondrial oxidative phosphorylation limits the self-renewal of T cells exposed to persistent antigen. After completing his training, Thompson became a physician at the National Naval Medical Center in Bethesda, Maryland, and an assistant professor of medicine at the Uniformed Services University of the Health Sciences. SOURCES: IRS Form 990, annual report or statement of individual nonprofit. Metabolic Profiling Reveals a Dependency of Human Metastatic Breast Cancer on Mitochondrial Serine and One-Carbon Unit Metabolism. Craig B. Thompson discloses the following relationships and financial interests: The information published here is for a specific annual disclosure period. Cell metabolism, 30(5), 865–876.e5. Zhu, J., Berisa, M., Schwörer, S., Qin, W., Cross, J. R., & Thompson, C. B. We believe the lack of a cell-intrinsic mechanism to regulate nutrient uptake provides the first and most fundamental barrier to cell transformation.

Metabolic Profiling Reveals a Dependency of Human Metastatic Breast Cancer on Mitochondrial Serine and One-Carbon Unit Metabolism. Just last year, he received $300,000 … Learn more about MSK’s COI policies here. The Thompson laboratory has proposed that the basis of metazoan cell survival is determined by the inability of cells to take up nutrients in a cell-autonomous fashion.

Another article detailed how a hospital vice president held a nearly $1.4 million stake in a newly public company as compensation for representing Memorial Sloan Kettering on its board. This work has contributed to the resurgent interest in cancer cell metabolism and may form the basis for translational therapies to exploit the metabolic addictions exhibited by cancer cells.

The EMBO journal, 39(8), e103334.

[24], While most of the details were not announced, the suit was settled with an agreement wherein Agios entered into a licensing agreement with the University of Pennsylvania regarding specific intellectual property.